EGFR and non-small cell lung carcinoma: At first, EGFR is supposed to be the effective therapeutic target for multiple human cancers, especially in NSCLC.30 However, in the past decade, we have seen that EGFR inhibitor widely face primary resistance (~60%) and rapidly generate acquired resistance (6–12 months).22, 23 When resistance mutations of EGFR inhibitors appeared, there was a need to find new EGFR inhibitors.